Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 2Phase 2 2Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Lymphoid 3Head & Neck 3Thoracic 2Genitourinary 2Dermatologic 2Breast 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Prostatic Neoplasms 1NSCLC 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Pharmaceutical Preparations × Thoracic × Clear all
NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
118 enrolled
Thoracic

NSCLC

NCT00285675 2006-05-31

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Novacea

Phase 2 Unknown
25 enrolled
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡